CYCC
Cyclacel
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
stock price surged significantly
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CYCC
Cyclacel Pharmaceuticals, Inc.
A biopharmaceutical company developing innovative medicines based on cancer cell biology
Biological Technology
Invalid Date
03/16/2004
NASDAQ Stock Exchange
12
12-31
Common stock
200 Connell Drive , Suite 1500, Berkeley Heights, New Jersey
--
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company established in 1996 and in the development stage, is dedicated to the development and commercialization of new drugs and organ-related drugs for the treatment of human cancer and other major diseases. Cyclacel is a pioneer in the field of cell cycle, and it dares to treat patients with new drugs that are only suitable for oral use. Its goal is to become a diversified biomedical company focusing on hematological and oncology research based on the development of its series of commercial products and new drug screening mechanisms. As a developing company, all the company's efforts contribute to its research and development, guide clinical trials, develop and acquire new intellectual property, improve capital reserves and profitability, and train employees. Its goal is to develop and commercialize small molecule drugs for the control of all stages of the cell cycle and for the treatment of cancer and other major diseases, especially those areas with large medical gaps.
Company Financials
EPS
CYCC has released its 2023 Q4 earnings. EPS was reported at -6.23, versus the expected -5.89, missing expectations. The chart below visualizes how CYCC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
